| Literature DB >> 35335013 |
Mateusz Babicki1, Wojciech Malchrzak1, Agnieszka Mastalerz-Migas1.
Abstract
Vaccination is the most effective tool to combat the COVID-19 pandemic. However, it is ineffective without appropriate public acceptance. In Poland, 53% of the country's population is vaccinated, which puts us in the last position among the EU countries. Therefore, this study aims to assess the main concerns regarding vaccination in the unvaccinated population of Poland. The study was based on an original questionnaire that was distributed online. There were three phases of the study: Phase 1-before the preventive vaccination plan, Phase 2-2 months after implementation of the programme, Phase 3-after 4 months when the immunisation rate in Poland was 42%. A total of 4459 individuals participated in the study. As many as 1943 participants were excluded from the analysis due to lack of consent (30 subjects) or COVID-19 vaccination (1913 subjects). Out of the remaining 2516 unvaccinated individuals, 463 were participants in the first phase of the study, 1137 in the second phase of the study, and 916 in the third phase. As the preventive vaccination plan in Poland continued, concerns about vaccine adverse events, safety and efficacy were raised. The only lower concern was that about the vaccine transportation rules. Moreover, as the vaccination programme continued, there was an increase in the percentage of individuals declaring their full reluctance towards vaccination against COVID-19. Conclusions: The Internet is the main source of knowledge about the COVID-19 vaccination, so it should be focused on during vaccination campaigns. The public is primarily concerned about adverse events of vaccines and the lack of appropriate tests of the products used. Therefore, it is advisable to popularise the current state of knowledge and promote reliable information concerning the COVID-19 vaccination.Entities:
Keywords: COVID-19; COVID-19 vaccination; attitudes towards vaccination
Year: 2022 PMID: 35335013 PMCID: PMC8955026 DOI: 10.3390/vaccines10030381
Source DB: PubMed Journal: Vaccines (Basel) ISSN: 2076-393X
Characteristics of the study group.
| Variable | Phase 1 | Phase 2 | Phase 3 | Total | |
|---|---|---|---|---|---|
| Sex | Male | 114 (24.6) | 222 (19.5) | 360 (39.3) | 696 (27.7) |
| Female | 349 (75.4) | 915 (80.5) | 556 (60.7) | 1820 (72.34) | |
| Age | 18–29 | 183 (39.5) | 626 (55.1) | 279 (30.5) | 1088 (43.2) |
| 30–39 | 131 (28.3) | 315 (27.7) | 333 (36.4) | 779 (31.0) | |
| 40–59 | 127 (27.4) | 153 (13.5) | 269 (29.4) | 549 (21.8) | |
| >59 | 22 (4.8) | 43 (3.8) | 35 (3.8) | 100 (4.0) | |
| Place of residence | City > 250 k population | 177 (38.2) | 471 (41.4) | 387 (42.2) | 1035 (41.1) |
| City/town of 50 k–250 k population | 103 (22.2) | 215 (18.8) | 196 (21.4) | 513 (20.4) | |
| Town of up to 50 k population | 87 (18.8) | 182 (16.0) | 152 (16.6) | 421 (16.7) | |
| Rural area | 96 (20.7) | 270 (23.7) | 181 (19.8) | 547 (21.7) | |
| Level of education | Higher (university degree) | 303 (65.4) | 687 (60.4) | 648 (70.7) | 1638 (65.1) |
| Secondary | 136 (29.4) | 397 (34.9) | 226 (24.7) | 759 (30.2) | |
| Vocational | 18 (3.9) | 35 (3.1) | 23 (2.5) | 76 (3.0) | |
| Lower secondary | 5 (1.1) | 8 (0.7) | 10 (1.1) | 23 (0.9) | |
| Primary | 1 (0.2) | 10 (0.9) | 9 (1.0) | 20 (0.8) | |
| Marital status | Married | 212 (45.8) | 461 (40.5) | 537 (58.6) | 1210 (48.1) |
| Domestic partnership/informal relationship | 147 (31.7) | 388 (34.1) | 206 (22.5) | 741 (29.5) | |
| Single | 104 (22.5) | 288 (25.3) | 173 (18.9) | 565 (22.5) | |
| Health professional | Yes | 108 (23.3) | 82 (7.2) | 87 (9.5) | 277 (11.0) |
| No | 355 (76.7) | 1055 (92.8) | 829 (90.5) | 2239 (89.0) | |
| Diagnosed with COVID-19 | No | 389 (84.0) | 938 (82.5) | 685 (74.8) | 2012 (80.0) |
| Yes, in the past | 69 (14.9) | 179 (15.7) | 230 (25.1) | 478 (19.0) | |
| Yes, currently | 5 (1.1) | 20 (1.8) | 1 (0.1) | 26 (1.0) | |
| Previous vaccinations | None | 24 (5.2) | 56 (4.9) | 61 (6.7) | 141 (5.6) |
| Only mandatory | 251 (54.2) | 700 (61.6) | 614 (67.0) | 1565 (62.2) | |
| Mandatory and recommended | 188 (40.6) | 381 (33.5) | 241 (26.3) | 810 (32.2) | |
| Chronic diseases | Yes | — | 381 (33.5) | 292 (31.9) | 673 (32.8) |
| No | — | 755 (66.4) | 624 (68.1) | 1379 (67.2) | |
| Opinion on mandatory vaccinations against COVID-19 | For | — | 372 (32.7) | 88 (9.6) | 460 (22.4) |
| Against | — | 580 (51.0) | 761 (56.8) | 1341 (65.4) | |
| No opinion | — | 184 (16.2) | 67 (7.3) | 251 (12.2) | |
| Willingness to vaccinate against COVID-19 | Yes, as soon as possible | 171 (36.9) | 509 (44.8) | 134 (14.6) | 814 (32.4) |
| Yes, in a few months | 52 (11.2) | 66 (5.8) | 48 (5.2) | 166 (6.6) | |
| Yes, in a year or more | 12 (2.6) | 22 (1.9) | 9 (1.0) | 43 (1.7) | |
| No, but I might consider it in the future | 81 (17.5) | 209 (18.4) | 269 (29.4) | 559 (22.2) | |
| No, never | 113 (24.4) | 254 (22.3) | 415 (45.3) | 782 (31.1) | |
| I am not able to make a decision | 34 (7.3) | 77 (6.8) | 41 (4.5) | 152 (6.0) | |
Concerns about COVID-19 vaccination.
| Concerns about COVID-19 Vaccination | Study Phase | Willingness to Vaccinate ( |
| Cramér’s V | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Percentage of Individuals with Concerns |
| Yes, as Soon as Possible | Yes, in a Few Months | Yes, in over a Year | No, I Will Consider It in the Future | No, Never | I Am Not Able to Make a Decision | ||||
| Vaccine adverse event | 1 | 240 (51.8) | 0.025 | 57 (23.8) | 26 (10.8) | 8 (3.3) | 53 (22.1) | 69 (28.8) | 27 (11.3) | <0.001 | 0.311 |
| 2 | 612 (53.8) | 198 (32.4) | 37 (6.1) | 15 (2.5) | 148 (24.2) | 153 (25.0) | 61 (10.0) | <0.001 | 0.291 | ||
| 3 | 537 (58.6) | 63 (11.7) | 28 (5.2) | 5 (0.9) | 168 (31.3) | 241 (44.9) | 32 (6.0) | 0.008 | 0.130 | ||
| Vaccines have not been appropriately tested | 1 | 235 (50.8) | <0.001 | 35 (14.9) | 30 (12.8) | 11 (4.7) | 66 (28.1) | 71 (30.2) | 22 (9.4) | <0.001 | 0.491 |
| 2 | 523 (46.0) | 77 (14.7) | 31 (5.9) | 12 (2.3) | 162 (31.0) | 181 (34.6) | 60 (11.5) | <0.001 | 0.575 | ||
| 3 | 583 (63.6) | 30 (5.2) | 24 (4.1) | 6 (1.0) | 219 (37.6) | 275 (47.2) | 29 (5.0) | <0.001 | 0.393 | ||
| Transport | 1 | 122 (26.3) | <0.001 | 53 (43.4) | 15 (12.3) | 4 (3.3) | 19 (15.6) | 23 (18.9) | 8 (6.6) | 0.422 | 0.103 |
| 2 | 175 (15.4) | 73 (41.7) | 13 (7.4) | 5 (2.9) | 29 (16.6) | 36 (20.6) | 19 (10.9) | 0.154 | 0.084 | ||
| 3 | 116 (12.7) | 10 (8.6) | 5 (4.3) | 1 (0.9) | 35 (30.2) | 62 (53.5) | 3 (2.6) | 0.256 | 0.084 | ||
| Vaccine efficacy | 1 | 98 (21.2) | <0.001 | 26 (26.5) | 7 (7.14) | 1 (1.0) | 21 (21.4) | 38 (38.8) | 5 (5.1) | 0.002 | 0.203 |
| 2 | 341 (30.0) | 71 (20.8) | 23 (6.7) | 9 (2.6) | 92 (27.0) | 116 (34.0) | 30 (8.8) | <0.001 | 0.320 | ||
| 3 | 307 (33.5) | 27 (8.8) | 8 (2.6) | 4 (1.3) | 107 (34.9) | 145 (47.2) | 16 (5.2) | <0.001 | 0.158 | ||
| The COVID-19 pandemic is a conspiracy | 1 | 66 (14.3) | 0.095 | 0 (0.0) | 0 (0.0) | 0 (0.0) | 7 (10.6) | 58 (87.9) | 1 (1.5) | <0.001 | 0.609 |
| 2 | 141 (12.4) | 1 (0.7) | 2 (1.4) | 0 (0.0) | 24 (17.0) | 113 (80.1) | 1 (0.7) | <0.001 | 0.537 | ||
| 3 | 144 (15.7) | 1 (0.7) | 1 (0.7) | 0 | 37 (25.7) | 103 (71.5) | 2 (1.4) | — | — | ||
| Other | 1 | 13 (2.8) | <0.001 | 8 (61.5) | 0 (0.0) | 0 (0.0) | 2 (15.4) | 3 (23.1) | 0 (0.0) | 0.408 | 0.105 |
| 2 | 76 (6.7) | 12 (15.8) | 1 (1.3) | 2 (2.6) | 19 (25.0) | 40 (52.6) | 2 (2.6) | <0.001 | 0.221 | ||
| 3 | 90 (9.8) | ||||||||||
| COVID-19 vaccination is a medical experiment | 1 | -- | ---- | — | — | — | — | — | — | — | — |
| 2 | -- | — | — | — | — | — | — | — | — | ||
| 3 | 257 (28.1) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 79 (30.7) | 176 (68.5) | 2 (0.8) | <0.001 | 0.374 | ||
| SARS-CoV-2 is not dangerous | 1 | -- | --- | — | — | — | — | — | — | — | — |
| 2 | -- | — | — | — | — | — | — | — | — | ||
| 3 | 158 (17.2) | 0 (0.0) | 1 (0.6) | 0 (0.0) | 50 (31.7) | 104 (65.8) | 3 (1.9) | <0.001 | 0.253 | ||
| Symptoms that may occur in the future | 1 | -- | ---- | — | — | — | — | — | — | — | — |
| 2 | -- | — | — | — | — | — | — | — | — | ||
| 3 | 581 (63.4) | 49 (8.4) | 27 (4.7) | 6 (1.0) | 203 (35.0) | 267 (46.0) | 29 (5.0) | <0.001 | 0.257 | ||
Chronic diseases in the context of willingness to be vaccinated against COVID-19.
| Variable | Phase | Willingness to Vaccinate ( |
| Cramér’s V | |||||
|---|---|---|---|---|---|---|---|---|---|
| Yes, as Soon as Possible | Yes, in a Few Months | Yes, in over a Year | No, I Will Consider It in the Future | No, Never | I Am Not Able to Make a Decision | ||||
| Chronic conditions | 1 | — | — | — | — | — | — | — | — |
| 2 | 192 (50.4) | 19 (5.0) | 8 (2.1) | 60 (15.8) | 77 (20.2) | 25 (6.6) | 0.141 | 0.085 | |
| 3 | 63 (21.6) | 24 (8.2) | 4 (1.4) | 78 (26.7) | 107 (36.6) | 16 (5.5) | <0.001 | 0.184 | |
| Cardiovascular diseases | 1 | — | — | — | — | — | — | — | — |
| 2 | 38 (51.4) | 3 (4.1) | 2 (2.7) | 14 (18.9) | 14 (18.9) | 3 (4.1) | 0.741 | 0.049 | |
| 3 | 11 (16.7) | 3 (4.6) | 0 (0.0) | 21 (31.8) | 24 (36.4) | 7 (10.6) | 0.139 | 0.095 | |
| Respiratory diseases | 1 | — | — | — | — | — | — | — | — |
| 2 | 34 (53.1) | 2 (3.1) | 1 (1.6) | 11 (17.2) | 11 (17.2) | 5 (7.8) | 0.710 | 0.051 | |
| 3 | 4 (8.5) | 2 (4.3) | 1 (2.1) | 10 (21.3) | 26 (55.3) | 4 (8.5) | 0.304 | 0.081 | |
| Neurological diseases | 1 | — | — | — | — | — | — | — | — |
| 2 | 10 (55.6) | 0 (0.0) | 0 (0.0) | 2 (11.1) | 5 (27.8) | 1 (5.6) | 0.745 | 0.049 | |
| 3 | 7 (38.9) | 1 (5.6) | 0 (0.0) | 5 (27.8) | 5 (27.8) | 0 (0.0) | 0.086 | 0.103 | |
| Oncological diseases | 1 | — | — | — | — | — | — | — | — |
| 2 | 9 (100.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0.047 | 0.099 | |
| 3 | 4 (36.4) | 0 (0.0) | 0 (0.0) | 3 (27.3) | 4 (36.4) | 0 (0.0) | 0.416 | 0.074 | |
| Mental disorders | 1 | — | — | — | — | — | — | — | — |
| 2 | 37 (46.3) | 6 (7.5) | 1 (1.3) | 11 (13.8) | 21 (26.3) | 4 (5.0) | 0.750 | 0.049 | |
| 3 | 16 (32.0) | 6 (12.0) | 0 (0.0) | 10 (20.0) | 12 (24.0) | 6 (12.0) | <0.001 | 0.180 | |
| Skin diseases | 1 | — | — | — | — | — | — | — | — |
| 2 | 21 (44.7) | 2 (4.3) | 1 (2.1) | 6 (12.8) | 12 (25.5) | 5 (10.6) | 0.798 | 0.046 | |
| 3 | 8 (22.9) | 1 (2.9) | 0 (0.0) | 7 (20.0) | 16 (45.7) | 3 (8.6) | 0.430 | 0.073 | |
| Endocrine disorders | 1 | — | — | — | — | — | — | — | — |
| 2 | 82 (48.5) | 11 (6.5) | 5 (3.0) | 32 (18.9) | 29 (17.2) | 10 (5.9) | 0.476 | 0.063 | |
| 3 | 30 (22.9) | 14 (10.7) | 4 (3.1) | 33 (25.2) | 45 (34.4) | 5 (3.8) | <0.001 | 0.174 | |
| Other diseases | 1 | — | — | — | — | — | — | — | — |
| 2 | 35 (43.8) | 4 (5.0) | 3 (3.8) | 12 (15.0) | 19 (23.8) | 7 (8.8) | 0.748 | 0.049 | |
| 3 | 15 (20.0) | 4 (5.3) | 0 (0.0) | 20 (26.7) | 29 (38.7) | 7 (9.3) | 0.172 | 0.092 | |
Sources of knowledge about vaccines and the willingness to vaccinate against COVID-19.
| Variable | Phase | Percentage of Participants Using a Particular Source of Knowledge [ | Willingness to Vaccinate ( |
| Cramér’s V | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
|
| Yes, as Soon as Possible | Yes, in a Few Months | Yes, in over a Year | No, I Will Consider It in the Future | No, Never | I Am Not Able to Make a Decision | |||||
| Internet | 1 | — | 0.001 | — | — | — | — | — | — | — | — |
| 2 | 915 (80.5) | 423 (46.2) | 56 (6.1) | 20 (2.2) | 163 (17.8) | 190 (20.8) | 63 (6.9) | 0.052 | 0.098 | ||
| 3 | 675 (73.7) | 107 (15.9) | 37 (5.5) | 8 (1.2) | 216 (32.0) | 270 (40.0) | 37 (5.5) | <0.001 | 0.186 | ||
| Television | 1 | — | <0.001 | — | — | — | — | — | — | — | — |
| 2 | 340 (29.9) | 139 (40.9) | 20 (5.9) | 9 (2.7) | 66 (19.4) | 77 (22.7) | 29 (8.5) | 0.375 | 0.069 | ||
| 3 | 186 (20.3) | 20 (10.8) | 18 (9.7) | 3 (1.6) | 62 (33.3) | 65 (35.0) | 18 (9.7) | <0.001 | 0.190 | ||
| Doctor | 1 | — | 0.063 | — | — | — | — | — | — | — | — |
| 2 | 387 (34.0) | 192 (49.6) | 22 (5.7) | 5 (1.3) | 69 (17.8) | 73 (18.9) | 26 (6.7) | 0.164 | 0.083 | ||
| 3 | 358 (39.1) | 60 (16.8) | 20 (5.6) | 4 (1.1) | 90 (25.1) | 167 (46.7) | 17 (4.8) | 0.305 | 0.081 | ||
| Health professional | 1 | — | 0.064 | — | — | — | — | — | — | — | — |
| 2 | 421 (37.0) | 188 (44.7) | 25 (5.9) | 6 (1.4) | 92 (21.9) | 85 (20.2) | 25 (5.9) | 0.195 | 0.081 | ||
| 3 | 294 (32.1) | 44 (15.0) | 13 (4.4) | 5 (1.7) | 82 (27.9) | 137 (46.6) | 13 (4.4) | 0.671 | 0.060 | ||
| Information leaflets | 1 | — | 0.932 | — | — | — | — | — | — | — | — |
| 2 | 184 (16.2) | 72 (39.1) | 10 (5.4) | 2 (1.1) | 41 (22.3) | 48 (26.1) | 11 (6.0) | 0.328 | 0.071 | ||
| 3 | 154 (16.8) | 23 (14.9) | 5 (3.3) | 2 (1.3) | 43 (27.9) | 70 (45.5) | 11 (7.1) | 0.456 | 0.071 | ||
| Friends | 1 | — | 0.013 | — | — | — | — | — | — | — | — |
| 2 | 258 (22.7) | 86 (33.3) | 11 (4.3) | 9 (3.5) | 56 (21.7) | 76 (29.5) | 20 (7.8) | <0.001 | 0.149 | ||
| 3 | 160 (17.5) | 22 (13.8) | 5 (3.1) | 2 (1.3) | 59 (36.9) | 64 (40.0) | 8 (5.0) | 0.225 | 0.087 | ||
| Other | 1 | — | <0.001 | — | — | — | — | — | — | — | — |
| 2 | 241 (21.2) | 440 (49.2) | 56 (6.3) | 18 (2.0) | 163 (18.2) | 157 (17.5) | 61 (6.8) | <0.001 | 0.237 | ||
| 3 | 132 (14.4) | 122 (15.6) | 45 (5.7) | 7 (0.9) | 236 (30.1) | 337 (43.0) | 37 (4.7) | 0.013 | 0.126 | ||
| Scientific sources | 1 | — | — | — | — | — | — | — | — | — | |
| 2 | — | — | — | — | — | — | — | — | — | ||
| 3 | 597 (65.2) | 62 (10.4) | 21 (3.5) | 6 (1.0) | 179 (30.0) | 309 (51.8) | 20 (3.4) | <0.001 | 0.237 | ||
Impact of sociodemographic variables on attitudes towards COVID-19 vaccination.
| Variable | Phase | Willingness to Vaccinate ( |
| Cramér’s V | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Yes, as Soon as Possible | Yes, in a Few Months | Yes, in over a Year | No, I Will Consider It in the Future | No, Never | I Am Not Able to Make a Decision | |||||
| Sex | Male | 1 | 32 (28.1) | 11 (9.7) | 4 (3.5) | 27 (23.7) | 36 (31.6) | 4 (3.5) | 0.019 | 0.171 |
| 2 | 92 (41.4) | 13 (5.68) | 2 (0.9) | 37 (16.7) | 69 (31.1) | 9 (4.1) | 0.010 | 0.115 | ||
| 3 | 21 (5.8) | 7 (1.9) | 5 (1.4) | 131 (36.4) | 191 (53.1) | 5 (1.4) | <0.001 | 0.286 | ||
| Female | 1 | 139 (39.8) | 41 (11.8) | 8 (2.3) | 54 (15.5) | 77 (22.1) | 30 (8.6) | 0.019 | 0.171 | |
| 2 | 417 (45.6) | 53 (5.8) | 20 (2.2) | 172 (18.8) | 185 (20.2) | 68 (7.4) | 0.010 | 0.115 | ||
| 3 | 113 (20.3) | 41 (7.4) | 4 (0.7) | 138 (24.8) | 224 (40.3) | 36 (6.5) | <0.001 | 0.286 | ||
| Age | 18–29 | 1 | 48 (26.2) | 21 (11.5) | 7 (3.8) | 43 (23.5) | 50 (27.3) | 14 (7.7) | 0.007 | 0.151 |
| 2 | 251 (40.1) | 36 (5.8) | 13 (2.1) | 138 (22.0) | 139 (22.2) | 49 (7.8) | 0.050 | 0.086 | ||
| 3 | 62 (22.2) | 23 (8.2) | 4 (1.4) | 89 (31.9) | 83 (29.8) | 18 (6.5) | <0.001 | 0.168 | ||
| 30–39 | 1 | 55 (42.0) | 12 (9.2) | 4 (3.1) | 17 (13.0) | 34 (26.0) | 9 (6.9) | 0.007 | 0.151 | |
| 2 | 154 (48.9) | 23 (7.3) | 6 (1.9) | 44 (14.0) | 70 (22.2) | 18 (5.7) | 0.050 | 0.086 | ||
| 3 | 51 (15.3) | 20 (6.0) | 4 (1.2) | 82 (24.6) | 158 (47.5) | 18 (5.4) | <0.001 | 0.168 | ||
| 40–59 | 1 | 52 (41.0) | 18 (14.2) | 1 (0.8) | 20 (15.8) | 27 (21.3) | 9 (7.1) | 0.007 | 0.151 | |
| 2 | 79 (51.6) | 6 (3.9) | 3 (2.0) | 23 (15.0) | 35 (22.9) | 10 (23.3) | 0.050 | 0.086 | ||
| 3 | 16 (6.0) | 5 (1.9) | 1 (0.4) | 89 (33.1) | 154 (57.3) | 4 (1.5) | <0.001 | 0.168 | ||
| >59 | 1 | 16 (72.7) | 1 (4.6) | 0 (0.0) | 1 (4.6) | 2 (9.1) | 2 (9.1) | 0.007 | 0.151 | |
| 2 | 25 (58.1) | 1 (2.3) | 0 (0.0) | 4 (9.3) | 10 (23.3) | 3 (7.0) | 0.050 | 0.086 | ||
| 3 | 5 (14.3) | 0 (0.0) | 0 (0.0) | 9 (25.7) | 20 (57.1) | 1 (2.9) | <0.001 | 0.168 | ||
| Place of residence | City > 250 k population | 1 | 81 (45.8) | 24 (13.6) | 5 (2.8) | 28 (15.8) | 26 (14.7) | 13 (7.3) | 0.019 | 0.143 |
| 2 | 254 (53.9) | 23 (4.9) | 10 (2.1) | 80 (17.0) | 83 (17.6) | 21 (4.5) | 0.001 | 0.106 | ||
| 3 | 53 (13.7) | 24 (6.2) | 4 (1.0) | 113 (29.2) | 182 (47.0) | 11 (2.8) | 0.558 | 0.070 | ||
| City/town of 50 k–250 k population | 1 | 81 (45.8) | 24 (13.5) | 5 (2.8) | 28 (15.8) | 26 (14.7) | 13 (7.3) | 0.019 | 0.143 | |
| 2 | 84 (39.3) | 11 (5.1) | 6 (2.8) | 41 (19.2) | 58 (27.1) | 14 (6.5) | 0.001 | 0.106 | ||
| 3 | 32 (16.3) | 4 (2.0) | 2 (1.0) | 56 (28.6) | 92 (46.9) | 10 (5.1) | 0.558 | 0.070 | ||
| Town of up to 50 k population | 1 | 27 (31.0) | 10 (11.5) | 1 (1.2) | 18 (20.7) | 24 (27.6) | 7 (8.1) | 0.019 | 0.143 | |
| 2 | 73 (40.1) | 13 (7.1) | 3 (1.7) | 18 (9.9) | 39 (21.4) | 18 (9.9) | 0.001 | 0.106 | ||
| 3 | 20 (13.2) | 9 (5.9) | 1 (0.7) | 42 (27.6) | 69 (45.4) | 11 (7.2) | 0.558 | 0.070 | ||
| Rural area | 1 | 26 (27.1) | 5 (5.2) | 4 (4.2) | 17 (17.7) | 36 (37.5) | 8 (8.3) | 0.019 | 0.143 | |
| 2 | 98 (36.3) | 19 (7.0) | 3 (1.1) | 52 (19.3) | 74 (27.4) | 24 (8.9) | 0.001 | 0.106 | ||
| 3 | 29 (16.0) | 11 (6.1) | 2 (1.1) | 58 (32.0) | 72 (39.8) | 9 (5.0) | 0.558 | 0.070 | ||
| Level of education | Higher (university degree) | 1 | 137 (45.2) | 36 (11.9) | 9 (3.0) | 50 (16.5) | 53 (17.5) | 18 (5.9) | <0.001 | 0.187 |
| 2 | 319 (46.4) | 46 (6.7) | 14 (2.0) | 132 (19.2) | 130 (18.9) | 46 (6.7) | 0.005 | 0.093 | ||
| 3 | 89 (13.7) | 31 (4.8) | 8 (1.2) | 197 (30.4) | 292 (45.1) | 31 (4.8) | 0.038 | 0.094 | ||
| Secondary | 1 | 30 (22.1) | 15 (11.0) | 3 (2.2) | 28 (20.6) | 45 (33.1) | 15 (11.0) | <0.001 | 0.187 | |
| 2 | 171 (43.1) | 16 (4.0) | 7 (1.8) | 73 (18.4) | 103 (25.9) | 27 (6.8) | 0.005 | 0.093 | ||
| 3 | 37 (16.4) | 16 (7.1) | 0 (0.0) | 64 (28.3) | 100 (44.3) | 9 (4.0) | 0.038 | 0.094 | ||
| Vocational | 1 | 3 (16.7) | 0 (0.0) | 0 (0.0) | 3 (16.7) | 12 (66.7) | 0 (0.0) | <0.001 | 0.187 | |
| 2 | 10 (28.6) | 1 (2.9) | 1 (2.9) | 3 (8.6) | 16 (45.7) | 4 (11.4) | 0.005 | 0.093 | ||
| 3 | 2 (8.7) | 0 (0.0) | 0 (0.0) | 5 (21.7) | 15 (65.2) | 1 (4.4) | 0.038 | 0.094 | ||
| Lower secondary | 1 | 1 (20.0) | 1 (20.0) | 0 (0.0) | 0 (0.0) | 3 (60.0) | 0 (0.0) | <0.001 | 0.187 | |
| 2 | 5 (62.5) | 0 | 0 | 0 | 3 (37.5) | 0 | 0.005 | 0.093 | ||
| 3 | 2 (20.0) | 0 (0.0) | 0 (0.0) | 1 (10.0) | 7 (70.0) | 0 (0.0) | 0.038 | 0.094 | ||
| Primary | 1 | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 1 (100.0) | <0.001 | 0.187 | |
| 2 | 4 (40.0) | 3 (30.0) | 0 | 1 (10.0) | 2 (20.0) | 0 | 0.005 | 0.093 | ||
| 3 | 4 (44.4) | 1 (11.1) | 1 (11.1) | 2 (22.2) | 1 (11.1) | 0 (0.0) | 0.038 | 0.094 | ||
| Marital status | Married | 1 | 98 (46.2) | 21 (9.9) | 3 (1.4) | 28 (13.2) | 51 (24.1) | 11 (5.2) | 0.012 | 0.157 |
| 2 | 229 (49.7) | 30 (6.5) | 10 (2.2) | 77 (16.7) | 89 (19.3) | 26 (5.6) | 0.098 | 0.084 | ||
| 3 | 75 (14.0) | 32 (6.0) | 4 (0.7) | 151 (28.1) | 255 (47.5) | 20 (3.7) | 0.247 | 0.083 | ||
| Domestic partnership/informal relationship | 1 | 42 (28.6) | 17 (11.6) | 6 (4.1) | 34 (23.1) | 38 (25.9) | 10 (6.8) | 0.012 | 0.157 | |
| 2 | 148 (38.1) | 19 (4.9) | 8 (2.1) | 80 (20.6) | 102 (26.3) | 31 (8.0) | 0.098 | 0.084 | ||
| 3 | 31 (15.1) | 8 (3.9) | 2 (1.0) | 57 (27.7) | 93 (45.2) | 15 (7.3) | 0.247 | 0.083 | ||
| Single | 1 | 31 (29.8) | 14 (13.5) | 3 (2.9) | 19 (18.3) | 24 (23.1) | 13 (12.5) | 0.012 | 0.157 | |
| 2 | 132 (45.8) | 17 (5.9) | 4 (1.4) | 80 (20.6) | 102 (26.3) | 20 (6.9) | 0.098 | 0.084 | ||
| 3 | 28 (16.2) | 8 (4.6) | 3 (1.7) | 61 (35.3) | 67 (38.7) | 6 (3.5) | 0.247 | 0.083 | ||
| Health professional | Yes | 1 | 64 (59.3) | 12 (11.1) | 2 (1.9) | 13 (12.0) | 9 (8.3) | 8 (7.4) | <0.001 | 0.281 |
| 2 | 26 (31.7) | 6 (7.3) | 2 (2.4) | 25 (30.5) | 16 (19.5) | 7 (8.5) | 0.041 | 0.101 | ||
| 3 | 8 (9.2) | 3 (3.5) | 1 (1.2) | 20 (23.0) | 53 (60.9) | 2 (2.3) | 0.068 | 0.105 | ||
| No | 1 | 107 (30.1) | 40 (11.3) | 10 (2.8) | 68 (19.2) | 104 (29.3) | 26 (7.3) | <0.001 | 0.281 | |
| 2 | 483 (45.8) | 60 (6.7) | 20 (1.9) | 184 (17.4) | 238 (22.6) | 70 (6.6) | 0.041 | 0.101 | ||
| 3 | 126 (15.2) | 45 (5.4) | 8 (1.0) | 249 (30.0) | 362 (43.7) | 39 (4.7) | 0.068 | 0.105 | ||
| Has COVID-19 been diagnosed? | No | 1 | 147 (37.8) | 41 (10.5) | 11 (2.8) | 66 (17.0) | 96 (24.7) | 28 (7.2) | 0.756 | 0.085 |
| 2 | 423 (45.1) | 53 (5.7) | 20 (2.1) | 159 (17.0) | 218 (23.2) | 65 (6.3) | 0.085 | 0.085 | ||
| 3 | 97 (14.2) | 30 (4.4) | 8 (1.2) | 200 (29.2) | 319 (46.6) | 31 (4.5) | 0.571 | 0.069 | ||
| Yes, in the past | 1 | 22 (31.9) | 11 (15.9) | 1 (1.5) | 15 (21.7) | 15 (21.7) | 5 (7.3) | 0.756 | 0.085 | |
| 2 | 73 (40.8) | 11 (6.2) | 2 (1.1) | 48 (26.8) | 33 (18.4) | 12 (6.7) | 0.085 | 0.085 | ||
| 3 | 37 (16.1) | 18 (7.8) | 1 (0.4) | 68 (29.6) | 96 (41.7) | 10 (4.4) | 0.571 | 0.069 | ||
| Yes, currently | 1 | 2 (40.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 2 (40.0) | 1 (20.0) | 0.756 | 0.085 | |
| 2 | 13 (65.0) | 2 (10.0) | 0 (0.0) | 2 (10.0) | 3 (15.0) | 0 (0.0) | 0.085 | 0.085 | ||
| 3 | 0 (0.0) | 0 (0.0) | 0 (0.0) | 1 (100.0) | 0 (0.0) | 0 (0.0) | 0.571 | 0.069 | ||
| Previous vaccinations | None | 1 | 1 (4.2) | 2 (8.3) | 0 (0.0) | 3 (12.5) | 16 (66.7) | 2 (8.3) | <0.001 | 0.358 |
| 2 | 13 (23.2) | 3 (5.4) | 0 (0.0) | 6 (10.7) | 33 (58.9) | 1 (1.8) | <0.001 | 0.255 | ||
| 3 | 4 (6.6) | 1 (1.6) | 0 (0.0) | 7 (11.5) | 49 (80.3) | 0 (0.0) | <0.001 | 0.157 | ||
| Only mandatory | 1 | 58 (23.1) | 21 (8.4) | 6 (2.4) | 59 (23.5) | 86 (34.3) | 21 (8.4) | <0.001 | 0.358 | |
| 2 | 250 (35.7) | 38 (5.4) | 12 (1.7) | 155 (22.1) | 190 (27.1) | 55 (7.9) | <0.001 | 0.255 | ||
| 3 | 79 (12.9) | 35 (5.7) | 6 (1.0) | 185 (30.1) | 280 (45.6) | 29 (4.7) | <0.001 | 0.157 | ||
| Mandatory and recommended | 1 | 112 (59.6) | 29 (15.4) | 6 (3.2) | 19 (10.1) | 11 (5.9) | 11 (5.9) | <0.001 | 0.358 | |
| 2 | 246 (64.6) | 25 (6.6) | 10 (2.6) | 48 (12.6) | 31 (8.1) | 21 (5.5) | <0.001 | 0.255 | ||
| 3 | 51 (21.2) | 12 (5.0) | 3 (1.2) | 77 (32.0) | 86 (35.7) | 12 (5.0) | <0.001 | 0.157 | ||